Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Issued
Ratios

Ligand Pharmaceuticals (LGNDZ) Shares Issued (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Shares Issued for 16 consecutive years, with $29.2 million as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 163.11% to $29.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $67.4 million for FY2025, N/A changed from the prior year.
  • Shares Issued hit $29.2 million in Q4 2025 for Ligand Pharmaceuticals, up from $8.2 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $29.2 million in Q4 2025 to a low of -$46.3 million in Q4 2024.
  • Historically, Shares Issued has averaged $4.2 million across 5 years, with a median of $3.8 million in 2023.
  • Biggest five-year swings in Shares Issued: skyrocketed 6192.87% in 2021 and later tumbled 1628.66% in 2023.
  • Year by year, Shares Issued stood at $4.3 million in 2021, then crashed by 142.79% to -$1.8 million in 2022, then tumbled by 584.6% to -$12.5 million in 2023, then tumbled by 268.97% to -$46.3 million in 2024, then skyrocketed by 163.11% to $29.2 million in 2025.
  • Business Quant data shows Shares Issued for LGNDZ at $29.2 million in Q4 2025, $8.2 million in Q2 2025, and $4.2 million in Q1 2025.